SXC Health Solutions' CEO Discusses Q1 2012 Results - Earnings Call Transcript

SXC Health Solutions (SXCI)

Q1 2012 Earnings Call

May 03, 2012 8:30 am ET

Executives

Mark A. Thierer - Chairman and Chief Executive Officer

Jeffrey Park - Chief Financial Officer, Principal Accounting Officer and Executive Vice President of Finance

Analysts

Bret D. Jones - Oppenheimer & Co. Inc., Research Division

Lawrence C. Marsh - Barclays Capital, Research Division

Andrew Schenker - Morgan Stanley, Research Division

George Hill - Citigroup Inc, Research Division

Brian Tanquilut - Jefferies & Company, Inc., Research Division

Brooks G. O'Neil - Dougherty & Company LLC, Research Division

Amanda Murphy - William Blair & Company L.L.C., Research Division

Robert M. Willoughby - BofA Merrill Lynch, Research Division

Presentation

Operator

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the SXC Health Solutions 2012 First Quarter Results Conference Call. The company issued an earnings press release this morning, which has been filed with the SEC on Form 8-K and is also available on the Investor Information section of SXC's website at sxc.com. Listeners are reminded that portions of today's discussions contain forward-looking statements that reflect current views with respect to future events such as SXC's outlook for future performance and the closing of the pending Catalyst transaction. Any such statements are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those projected in the forward-looking statements. Please refer to the company's filings with the SEC for additional information on risk factors. We would also like to advise you that all forward-looking statements made on today's call are intended to fall within the Safe Harbor provisions of the Private Securities and Litigation Reform Act of 1995.

During the call, we will also discuss some items that do not conform to generally accepted accounting principles, including EBITDA and adjusted EPS. We have reconciled those items to the most comparable GAAP measures in the earnings release and in the Form 10-Q that will be filed with the SEC. Neither EBITDA nor adjusted EPS should be considered as an alternative to net income or cash flows from operating activities or any other performance or liquidity measure derived in accordance with GAAP.

I would like to remind everyone that this call is being recorded on Thursday, May 3, 2012, at 8:30 a.m. Eastern Time. A replay of today's call will be available at sxc.com approximately 1 hour after the conclusion of this call. Any redistribution, retransmission or rebroadcast of this call in any form without the express written consent of SXC is strictly prohibited. [Operator Instructions] I would now like to turn the conference over to Mr. Mark Thierer, Chairman and CEO. Please go ahead, sir.

Mark A. Thierer

Well, thank you, and good morning, everyone. We appreciate you joining us today. We're pleased to report that we've had a very strong start to the new year, posting record results across the board. For the first quarter of 2012, SXC delivered $1.7 billion in revenue and $54 million in EBITDA, representing significant growth over the first quarter last year.

I'll discuss the highlights of our first quarter momentarily. But first, I wanted to take the opportunity to comment on our recently announced merger with Catalyst Health Solutions. We are very excited about this strategic combination. By joining the industry's fastest growing middle market players, we will create the second largest independent PBM in the country in terms of prescription volume. Most companies are very successful and highly complementary. SXC's flexible and scalable Technology Solutions, combined with Catalyst's client-centric philosophy to pharmacy benefit management, will provide a true unique offering to the marketplace. The combined company will improve our competitive position by providing a scaled and legitimate alternative model to the payers searching for an enhanced pharmacy solution. The combined company will have greater ability to control pharmacy costs for our clients while offering a level of flexibility truly unique to this industry. We intend to use our skill and scale to drive better value for our clients.

I'm very pleased with the talent we're seeing at Catalyst. David Blair and Rick Bates have fielded a truly strong team. According to many of the top industry consultants, Catalyst has built one of the industry's strongest sales and marketing machines at the heart of which is their Center of Excellence service model. Our intention is to marry Catalyst proven service model with SXC's industry-leading technology footprint to create a truly disruptive alternative model to the big 3, now the big 2.

We continue to be excited by the opportunity to further expand and diversify our client base. Historically, both companies have been successful selling to the middle market. In addition, SXC services many of the messy markets, unique markets that we call hard to organize like Fee-For-Service Medicaid, long-term care and workers' compensation. We've experienced significant successes well in the health plan market while Catalyst has experienced success selling to larger employers. We believe our clients, prospects and consultants alike will find the new depth and breadth of our combined capabilities, be advantageous and highly compelling.

Now from a strategy standpoint, we believe it's critically important to engage the chain drug stores and the full retail network and, in particular, Walgreens, to drive the most competitive network offering for our clients. We're seeing demand for mandatory mail-order programs, and as such PBMs need a strong network offering in order to compete. We enjoy a strong working relationship with Walgreens, as well as the other major retailers in this industry, and we intend to keep it that way.

Read the rest of this transcript for free on seekingalpha.com

More from Stocks

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says